91 related articles for article (PubMed ID: 8846041)
1. Microtubule changes in hematologic malignant cells treated with paclitaxel and comparison with vincristine cytotoxicity.
Hirose Y; Takiguchi T
Blood Cells Mol Dis; 1995; 21(2):119-30. PubMed ID: 8846041
[TBL] [Abstract][Full Text] [Related]
2. Microtubule organization in lymphoid malignancies.
Hirose Y; Konda S
Blood Cells; 1992; 18(2):225-38; discussion 239-40. PubMed ID: 1450424
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
Kurtzberg LS; Roth SD; Bagley RG; Rouleau C; Yao M; Crawford JL; Krumbholz RD; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1029-38. PubMed ID: 19277662
[TBL] [Abstract][Full Text] [Related]
4. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
Rowinsky EK; Donehower RC; Jones RJ; Tucker RW
Cancer Res; 1988 Jul; 48(14):4093-100. PubMed ID: 2898289
[TBL] [Abstract][Full Text] [Related]
5. Bcl-xL is phosphorylated in malignant cells following microtubule disruption.
Poruchynsky MS; Wang EE; Rudin CM; Blagosklonny MV; Fojo T
Cancer Res; 1998 Aug; 58(15):3331-8. PubMed ID: 9699663
[TBL] [Abstract][Full Text] [Related]
6. Antimicrotubular and cytotoxic activity of geiparvarin analogues, alone and in combination with paclitaxel.
Miglietta A; Bocca C; Gabriel L; Rampa A; Bisi A; Valenti P
Cell Biochem Funct; 2001 Sep; 19(3):181-9. PubMed ID: 11494307
[TBL] [Abstract][Full Text] [Related]
7. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
[TBL] [Abstract][Full Text] [Related]
8. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death.
Blagosklonny MV; Giannakakou P; el-Deiry WS; Kingston DG; Higgs PI; Neckers L; Fojo T
Cancer Res; 1997 Jan; 57(1):130-5. PubMed ID: 8988053
[TBL] [Abstract][Full Text] [Related]
9. Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines.
Whang YM; Park KH; Jung HY; Jo UH; Kim YH
Cancer; 2009 Mar; 115(6):1253-66. PubMed ID: 19156899
[TBL] [Abstract][Full Text] [Related]
10. Effect of drugs affecting microtubular assembly on microtubules, phospholipid synthesis and physiological indices (signalling, growth, motility and phagocytosis) in Tetrahymena pyriformis.
Kovács P; Csaba G
Cell Biochem Funct; 2006; 24(5):419-29. PubMed ID: 15912561
[TBL] [Abstract][Full Text] [Related]
11. Implication of bax in apoptosis depends on microtubule network mobility.
Longuet M; Serduc R; Riva C
Int J Oncol; 2004 Aug; 25(2):309-17. PubMed ID: 15254727
[TBL] [Abstract][Full Text] [Related]
12. Microtubule-interfering activity of parthenolide.
Miglietta A; Bozzo F; Gabriel L; Bocca C
Chem Biol Interact; 2004 Oct; 149(2-3):165-73. PubMed ID: 15501437
[TBL] [Abstract][Full Text] [Related]
13. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis.
Stewart ZA; Mays D; Pietenpol JA
Cancer Res; 1999 Aug; 59(15):3831-7. PubMed ID: 10447002
[TBL] [Abstract][Full Text] [Related]
14. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.
Kamath K; Jordan MA
Cancer Res; 2003 Sep; 63(18):6026-31. PubMed ID: 14522931
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs.
Carles G; Braguer D; Dumontet C; Bourgarel V; Gonçalves A; Sarrazin M; Rognoni JB; Briand C
Br J Cancer; 1999 Jun; 80(8):1162-8. PubMed ID: 10376967
[TBL] [Abstract][Full Text] [Related]
16. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
Ong V; Liem NL; Schmid MA; Verrills NM; Papa RA; Marshall GM; Mackenzie KL; Kavallaris M; Lock RB
J Pharmacol Exp Ther; 2008 Feb; 324(2):434-42. PubMed ID: 17986648
[TBL] [Abstract][Full Text] [Related]
17. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
[TBL] [Abstract][Full Text] [Related]
18. [Immunofluorescent studies on cytoplasmic microtubule complex (CMTC) of Vero cells treated with 5,6-diphenylpyridazin-3-one derivatives].
Liu ZL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1990 Jun; 12(3):213-6. PubMed ID: 1981866
[TBL] [Abstract][Full Text] [Related]
19. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
